Search Results

Keyword:Isotopes

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

Research reactors provide critical support for global medical, scientific, and industrial innovation

Research reactors provide critical support for global medical, scientific, and industrial innovation

The International Atomic Energy Agency recently reported that research reactors continue to play a vital role in medical, scientific, industrial innovation, and nuclear workforce development, serving as key infrastructure for many countries to build their nuclear science and technology capabilities. Currently, 228 research reactors are in operation across 54 countries worldwide, with another 23 under construction or in the planning stage. Unlike nuclear power reactors used for electricity generation, research reactors primarily produce neutrons for applications in medicine, industry, agriculture, geological sciences, forensics, and other fields. With capabilities such as neutron irradiation, neutron imaging, elemental analysis, and radioisotope production, research reactors have become important platforms for advancing peaceful nuclear technology applications. In the medical field, research...

2026-08-23

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19

ASP Isotopes Subsidiary Evaluates Metal Hydrofluorination and Fluorination Project in Namibia

ASP Isotopes Subsidiary Evaluates Metal Hydrofluorination and Fluorination Project in Namibia

ASP Isotopes Inc. recently announced that its wholly-owned subsidiary, Quantum Leap Energy LLC, is evaluating metal conversion opportunities in Namibia, with work focusing on technologies and processes required for critical stages of the fission and fusion nuclear fuel cycles. According to the disclosure, the evaluation includes plans to construct a pilot-scale hydrofluorination and fluorination facility in the Walvis Bay area of Namibia. Public environmental and social impact assessments and consultation procedures for the project have already been initiated. The proposed facility will be used to develop, test, and demonstrate metal hydrofluorination and fluorination processes. In accordance with Namibian regulatory requirements, relevant public consultation notices have been published through customary local channels. The company...

2026-08-19

Kazakhstan's Institute of Nuclear Physics Plans to Expand Medical Radioisotope Production and Export

Kazakhstan's Institute of Nuclear Physics Plans to Expand Medical Radioisotope Production and Export

The Institute of Nuclear Physics (INP) of Kazakhstan is progressively expanding the applications of radioisotopes and radiation technologies, with related products already used in cancer diagnosis and treatment, industrial production, and scientific research. Institute Director Sayabek Sakhiyev stated that radioisotope and radiopharmaceutical production is one of the institute's key applied activities, covering the full chain from scientific research and research reactor operation to radiochemical technology development and medical applications. Currently, INP produces three main categories of radiopharmaceuticals: sodium iodide I-131 for thyroid disease treatment, Mo-99/Tc-99m related products for radionuclide diagnostics, and...

2026-08-18

Libya Plans to Restore Tajoura Research Reactor for Medical Isotope Production

Libya Plans to Restore Tajoura Research Reactor for Medical Isotope Production

The Libyan Atomic Energy Establishment recently proposed a plan to restore and restart the Tajoura nuclear research reactor for the production of medical radioisotopes. The establishment stated that this initiative aims to support the diagnosis and treatment of diseases and tumors, while reducing dependence on imports of relevant isotopes. Radioisotopes are essential materials in nuclear medicine, serving as tracers in medical imaging to help track organ function and detect certain diseases and tumors; some isotopes are also used in radiotherapy targeting specific tissues. According to the Libyan Atomic Energy Establishment, the Tajoura reactor has a rated thermal power of 10 megawatts and holds potential for producing various medical isotopes, including...

2026-08-18

Oak Ridge National Laboratory marks 80 years of isotope research and production, with applications spanning medicine, industry, and scientific research

Oak Ridge National Laboratory marks 80 years of isotope research and production, with applications spanning medicine, industry, and scientific research

On August 2, 1946, the Clinton Laboratories in Oak Ridge, Tennessee, held the first formal ceremony to deliver reactor-produced radioactive isotopes. A shipment of carbon-14 was sent from there to the Barnard Free Skin and Cancer Hospital in St. Louis, Missouri. Over the past 80 years, this event has been regarded as the starting point of Oak Ridge National Laboratory's isotope research and production endeavors, and also marked the beginning of broader civilian applications for reactor-produced radioactive isotopes. After World War II, the U.S. scientific community began exploring peaceful uses of atomic energy, with radioactive isotopes becoming an important direction. As unstable variants of elements, radioactive isotopes release radiation during decay and can be used...

2026-08-15

Philippine Steel Plant in Davao Raided: Radioactive Isotopes Detected in Finished Rebar and Multiple Materials at the Facility

Philippine Steel Plant in Davao Raided: Radioactive Isotopes Detected in Finished Rebar and Multiple Materials at the Facility

On August 14, Philippine authorities conducted a raid on Davao Mighty Steel Corp., a steel manufacturing plant located in Barangay Ilang, Bunawan District, Davao City. The operation followed an investigation launched by the National Bureau of Investigation (NBI) after receiving reports that the company was involved in the production and sale of substandard steel rebar, with the scope of the investigation subsequently expanding after radioactive isotopes were detected in commercially sold DMS rebar. The operation was led by the National Bureau of Investigation, with the participation of the Presidential Anti-Organized Crime Commission (PAOCC), and was supported by the Philippine Nuclear Research Institute (PNRI), the Philippine Air Force, the Philippine Coast Guard's Chemical, Biological, Radiological and Nuclear emergency response units, the Coast Guard Special Operations Group, and the Army's 10th Infantry Division.

2026-08-15

ASP Isotopes Plans Commercial Delivery of Multiple Stable Isotopes in Second Half of 2026

ASP Isotopes Plans Commercial Delivery of Multiple Stable Isotopes in Second Half of 2026

ASP Isotopes Inc. recently presented its expansion plans for isotope production, radiopharmaceuticals, and helium operations at Canaccord Genuity's 46th Annual Growth Conference. The company aims to begin commercial delivery of stable isotopes including silicon-28, carbon-14, and ytterbium-176 in the second half of 2026. Victor Petkov, the company's Chief Commercial Officer, stated that ASP Isotopes is leveraging its proprietary enrichment technology to serve electronics, nuclear medicine, and nuclear fuel-related markets. Currently, the company operates three production facilities in Pretoria, South Africa, primarily producing silicon-28 for semiconductor applications, as well as carbon-14 and ytterbium-176 for nuclear medicine-related uses. Regarding isotope supply...

2026-08-13

Full-Process Commissioning of Major Marine Isotope Separation Pilot Facility

Full-Process Commissioning of Major Marine Isotope Separation Pilot Facility

Shanghai Jiao Tong University's Changxing Ocean Laboratory is dedicated to building a quasi-industrial research platform for high-end marine equipment. The Marine Isotope Separation Applied Research Center, focusing on the industrial context of isotope production, separation, and application, and supported by the ministerial-level Isotope Separation Science and Technology Center, conducts research and development of key isotope separation technologies and engineering equipment for Generation III reactors, Generation IV reactors, and fusion reactors, establishing an innovative platform integrating R&D, testing, validation, data, and technical services. Major research facility: Recently, the construction of the hundred-ton-per-year light water hydrogen isotope separation pilot platform has achieved phased results, with the system facility undergoing full-process commissioning. The platform adopts a self-developed water distillation coupled with cryogenic hydrogen isotope separation process, achieving large-scale efficient separation and enrichment of hydrogen isotopes from light water. The platform's outcomes hold broad engineering application value in fields such as pressurized water reactor wastewater treatment, deuterium-tritium isotope separation, fusion tritium plant operation, and heavy water/heavy hydrogen production. At 18:00 on August 4, 2026, at the Marine Isotope Separation Applied Research Center of Changxing Ocean Laboratory, the hundred-ton-per-year light water hydrogen isotope separation pilot facility was commissioned through its full process! The commissioning and operation of this pilot facility was undertaken by the Marine Isotope Separation Applied Research Center, with all departments coordinating collaboratively, making meticulous arrangements, and dedicating full efforts. During the operation, the team successively overcame multiple challenges including tight schedules, heavy workloads, and persistent high temperatures. This achievement not only fully validated the stability and reliability of the process platform but also demonstrated the researchers' responsibility and commitment in rising to challenges and persevering diligently. In the next phase, the project technical team will continue to deepen process optimization based on existing achievements, focus on advancing continuous and stable facility operation, accelerate engineering application, and provide strong support for breakthroughs in key core technologies in China's hydrogen isotope separation field.

2026-08-13

Leshan Accelerates Construction of Medical Isotope Production Base to Promote Domestic Substitution of "Anti-Cancer Nuclear Drugs"

Leshan Accelerates Construction of Medical Isotope Production Base to Promote Domestic Substitution of "Anti-Cancer Nuclear Drugs"

On August 11, at the Leshan special press conference of "Myriad Scenes in Sichuan · Embarking on the '15th Five-Year Plan'", Leshan Mayor Zhao Yingchun stated that Leshan is accelerating the construction of the largest and most comprehensive medical isotope production base in China. Upon completion, the project will help break the foreign monopoly and import dependence on related products, promote the domestic substitution of anti-cancer nuclear drugs, and enable more patients to access domestically produced drugs with lower prices and better efficacy. Zhao Yingchun noted that during the "14th Five-Year Plan" period, Leshan has focused on building the "China Green Silicon Valley", a world-class tourist destination, and a major regional transportation and logistics hub in the province, continuously promoting high-quality development, with its economic output surpassing 250 billion yuan...

2026-08-12

Brookhaven National Laboratory Pilots Training Program for Nuclear Technology and Radiochemistry Talent

Brookhaven National Laboratory Pilots Training Program for Nuclear Technology and Radiochemistry Talent

The U.S. Department of Energy's Brookhaven National Laboratory and Suffolk County Community College (SUNY Suffolk) recently completed a pilot program to train talent in nuclear technology and radiochemistry. Eleven students and recent graduates completed one semester of coursework and three weeks of intensive laboratory training, becoming the first cohort to complete the Nuclear Technology and Radiochemistry Technician Pathway (NTRTP) program. SUNY Suffolk student Arin Morton (left) works under the guidance of mentor Michael Chimes at Brookhaven National Laboratory's Isotope Research and Production Division...

2026-08-11

Argentine CNEA Expert Appointed Vice Chair of European Working Group on Nuclear Medicine Isotope Supply Security

Argentine CNEA Expert Appointed Vice Chair of European Working Group on Nuclear Medicine Isotope Supply Security

The Argentine National Atomic Energy Commission (CNEA) recently announced that Daniel Sestao, an engineer and the institution's radioisotope production manager, has been appointed Vice Chair of the Supply Security Working Group of the European Association of Nuclear Medicine. CNEA, which operates under the Nuclear Affairs Secretariat of Argentina's Ministry of Economy, views this appointment as recognition of its technical capabilities in nuclear medicine and its role in international collaboration. The Supply Security Working Group is composed of international experts and focuses on the continuity and sustainability of the medical radioisotope supply chain, covering strategic isotopes such as molybdenum-99, technetium-99m, and lutetium-177. These radioisotopes are widely used in the diagnosis and treatment of tumors and complex diseases, forming a critical component of the nuclear medicine system...

2026-08-11

Russian Ambassador Says Willing to Transfer Civilian Nuclear Technology to Morocco, Covering Power Generation, Seawater Desalination, Nuclear Medicine, and Agriculture

Russian Ambassador Says Willing to Transfer Civilian Nuclear Technology to Morocco, Covering Power Generation, Seawater Desalination, Nuclear Medicine, and Agriculture

New directions are emerging in Morocco-Russia economic and technical cooperation, with both sides intending to expand the scope of collaboration from traditional energy sectors to strategic industries such as civilian nuclear technology, seawater desalination, medicine, and agriculture. Russia's Ambassador to Morocco, Igor Belyaev, stated that Russia is willing to share civilian nuclear technology expertise with Morocco, a remark indicating that bilateral cooperation may extend from equipment supply and energy projects to more technology-intensive comprehensive partnerships. This development is closely linked to Morocco's current needs. In recent years, Morocco has continuously promoted the diversification of energy sources and accelerated efforts to address water scarcity, with seawater desalination having become a...

2026-08-10